MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/
Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs
Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical c
Researchers have estimated that almost one in three men worldwide is infected with at least one genital human papillomavirus (HPV) strain, and one in five is harbouring st
A phase 3 trial of Merck & Co’s checkpoint inhibitor Keytruda could support the expansion of its use in cervical cancer to include newly-diagnosed patients with less s
Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe
UK researchers say they have developed an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.